JP2017526615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526615A5 JP2017526615A5 JP2016569715A JP2016569715A JP2017526615A5 JP 2017526615 A5 JP2017526615 A5 JP 2017526615A5 JP 2016569715 A JP2016569715 A JP 2016569715A JP 2016569715 A JP2016569715 A JP 2016569715A JP 2017526615 A5 JP2017526615 A5 JP 2017526615A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- acid sequence
- gitr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 300
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 137
- 102000047758 human TNFRSF18 Human genes 0.000 claims description 137
- 238000000034 method Methods 0.000 claims description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 74
- 239000011324 bead Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 55
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 41
- 102000053830 human TNFSF18 Human genes 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 229910052721 tungsten Inorganic materials 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 34
- 229910052727 yttrium Inorganic materials 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 32
- 108091008874 T cell receptors Proteins 0.000 claims description 30
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 30
- 230000008878 coupling Effects 0.000 claims description 25
- 238000010168 coupling process Methods 0.000 claims description 25
- 238000005859 coupling reaction Methods 0.000 claims description 25
- 229910052731 fluorine Inorganic materials 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 19
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 19
- 229910052740 iodine Inorganic materials 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 239000005557 antagonist Substances 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 229910052698 phosphorus Inorganic materials 0.000 claims description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 13
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 102000003945 NF-kappa B Human genes 0.000 claims description 11
- 108010057466 NF-kappa B Proteins 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 229910052720 vanadium Inorganic materials 0.000 claims description 10
- 102220469588 Voltage-dependent L-type calcium channel subunit beta-2_D60A_mutation Human genes 0.000 claims description 9
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 9
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 102220013477 rs117560775 Human genes 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 230000000735 allogeneic effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 6
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 6
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 claims description 5
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical group NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims description 5
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims description 5
- 229950006370 epacadostat Drugs 0.000 claims description 5
- 229950009034 indoximod Drugs 0.000 claims description 5
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 241000711549 Hepacivirus C Species 0.000 claims description 4
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 4
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 4
- 101000604674 Homo sapiens Immunoglobulin kappa variable 4-1 Proteins 0.000 claims description 4
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101001047520 Homo sapiens Probable non-functional immunoglobulin kappa variable 3-7 Proteins 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 102100038198 Immunoglobulin kappa variable 4-1 Human genes 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100022959 Probable non-functional immunoglobulin kappa variable 3-7 Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 210000003651 basophil Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000003979 eosinophil Anatomy 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 210000003630 histaminocyte Anatomy 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 3
- 210000004180 plasmocyte Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 208000009889 Herpes Simplex Diseases 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000998950 Homo sapiens Immunoglobulin heavy variable 1-18 Proteins 0.000 claims description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 2
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims description 2
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims description 2
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 claims description 2
- 101000989065 Homo sapiens Immunoglobulin heavy variable 7-4-1 Proteins 0.000 claims description 2
- 102100036884 Immunoglobulin heavy variable 1-18 Human genes 0.000 claims description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 2
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims description 2
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims description 2
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 claims description 2
- 102100029420 Immunoglobulin heavy variable 7-4-1 Human genes 0.000 claims description 2
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 2
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 230000037364 MAPK/ERK pathway Effects 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 2
- 229940121678 PD-L2 antagonist Drugs 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 241000589516 Pseudomonas Species 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 241000187747 Streptomyces Species 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 2
- 102000004398 TNF receptor-associated factor 1 Human genes 0.000 claims description 2
- 108090000920 TNF receptor-associated factor 1 Proteins 0.000 claims description 2
- 102000004393 TNF receptor-associated factor 2 Human genes 0.000 claims description 2
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 claims description 2
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 claims description 2
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 claims description 2
- 102000003715 TNF receptor-associated factor 4 Human genes 0.000 claims description 2
- 108090000008 TNF receptor-associated factor 4 Proteins 0.000 claims description 2
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 claims description 2
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010047741 Vulval cancer Diseases 0.000 claims description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 201000011165 anus cancer Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 230000003352 fibrogenic effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000005102 vulva cancer Diseases 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004071P | 2014-05-28 | 2014-05-28 | |
| US62/004,071 | 2014-05-28 | ||
| US201562161250P | 2015-05-13 | 2015-05-13 | |
| US62/161,250 | 2015-05-13 | ||
| PCT/US2015/032895 WO2015184099A1 (en) | 2014-05-28 | 2015-05-28 | Anti-gitr antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238784A Division JP2020048584A (ja) | 2014-05-28 | 2019-12-27 | 抗ｇｉｔｒ抗体及びその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526615A JP2017526615A (ja) | 2017-09-14 |
| JP2017526615A5 true JP2017526615A5 (enExample) | 2018-07-05 |
| JP6847666B2 JP6847666B2 (ja) | 2021-03-24 |
Family
ID=53433276
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569715A Active JP6847666B2 (ja) | 2014-05-28 | 2015-05-28 | 抗ｇｉｔｒ抗体及びその使用法 |
| JP2019238784A Pending JP2020048584A (ja) | 2014-05-28 | 2019-12-27 | 抗ｇｉｔｒ抗体及びその使用法 |
| JP2022202168A Pending JP2023021446A (ja) | 2014-05-28 | 2022-12-19 | 抗ｇｉｔｒ抗体及びその使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019238784A Pending JP2020048584A (ja) | 2014-05-28 | 2019-12-27 | 抗ｇｉｔｒ抗体及びその使用法 |
| JP2022202168A Pending JP2023021446A (ja) | 2014-05-28 | 2022-12-19 | 抗ｇｉｔｒ抗体及びその使用法 |
Country Status (27)
| Country | Link |
|---|---|
| US (9) | US10155818B2 (enExample) |
| EP (2) | EP3498295A1 (enExample) |
| JP (3) | JP6847666B2 (enExample) |
| KR (2) | KR102433464B1 (enExample) |
| CN (2) | CN108064242B (enExample) |
| AU (3) | AU2015266958A1 (enExample) |
| CA (1) | CA2949998A1 (enExample) |
| CY (1) | CY1124787T1 (enExample) |
| DK (1) | DK3148579T3 (enExample) |
| EA (1) | EA201692458A1 (enExample) |
| ES (1) | ES2860751T3 (enExample) |
| HR (1) | HRP20210364T1 (enExample) |
| HU (1) | HUE053857T2 (enExample) |
| IL (3) | IL293212B2 (enExample) |
| LT (1) | LT3148579T (enExample) |
| MA (2) | MA40041B1 (enExample) |
| MX (2) | MX377844B (enExample) |
| NZ (2) | NZ764826A (enExample) |
| PH (2) | PH12016502345B1 (enExample) |
| PL (1) | PL3148579T3 (enExample) |
| PT (1) | PT3148579T (enExample) |
| RS (1) | RS61678B1 (enExample) |
| SG (2) | SG11201609721WA (enExample) |
| SI (1) | SI3148579T1 (enExample) |
| SM (1) | SMT202100116T1 (enExample) |
| TW (2) | TW202132337A (enExample) |
| WO (1) | WO2015184099A1 (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| KR101549637B1 (ko) | 2012-06-08 | 2015-09-03 | 국립암센터 | 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도 |
| IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| JP6449338B2 (ja) | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| ES2810856T3 (es) | 2015-06-03 | 2021-03-09 | Bristol Myers Squibb Co | Anticuerpos ANTI-GITR para diagnóstico de cáncer |
| CA2991690A1 (en) * | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory t cells and use of same in immunotherapy |
| KR20180031728A (ko) | 2015-07-23 | 2018-03-28 | 인히브릭스 엘피 | 다가 및 다중특이적 gitr 결합 융합 단백질 |
| US11059899B1 (en) | 2015-10-22 | 2021-07-13 | Ablynx N.V. | Polypeptides that bind glucocorticoid-induced TNFR family-related receptor (GITR) |
| HK1253049A1 (zh) | 2015-11-12 | 2019-06-06 | Seagen Inc. | 糖基相互作用化合物及其使用方法 |
| SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| WO2017096276A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| EP3383431A4 (en) * | 2015-12-02 | 2019-08-28 | Agenus Inc. | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF |
| CA3007233A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| CN109069639B (zh) | 2016-03-08 | 2022-07-08 | 詹森生物科技公司 | Gitr抗体、方法及用途 |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| WO2017201502A1 (en) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | Adenovirus and immunomodulator combination therapy |
| CN115304669A (zh) | 2016-06-08 | 2022-11-08 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| CA3027121A1 (en) | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| JP2019519536A (ja) | 2016-07-01 | 2019-07-11 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法 |
| KR102899060B1 (ko) | 2016-07-14 | 2025-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| US20190330360A1 (en) * | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| KR102534568B1 (ko) * | 2016-07-22 | 2023-05-18 | 다나-파버 캔서 인스티튜트 인크. | 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr) 항체 및 이의 이용 방법 |
| EP3538152A4 (en) * | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
| US20200247902A1 (en) * | 2016-11-17 | 2020-08-06 | Seattle Genetics, Inc. | Compositions and methods for treating cancer |
| JOP20190100A1 (ar) * | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
| WO2018138521A1 (en) * | 2017-01-27 | 2018-08-02 | Ultrahuman One Limited | Binding agents |
| KR20190117467A (ko) * | 2017-02-10 | 2019-10-16 | 주식회사 유틸렉스 | IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도 |
| CA3054289A1 (en) | 2017-02-21 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
| KR102653141B1 (ko) | 2017-03-03 | 2024-04-01 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| IL300964A (en) | 2017-05-12 | 2023-04-01 | Harpoon Therapeutics Inc | mesothelin binding proteins |
| JP7274426B2 (ja) | 2017-05-16 | 2023-05-16 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｇｉｔｒアゴニスト抗体での癌の処置 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN109136275B (zh) | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化gitr基因改造动物模型的制备方法及应用 |
| WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| JP2020525483A (ja) | 2017-06-27 | 2020-08-27 | ノバルティス アーゲー | 抗ｔｉｍ−３抗体のための投与レジメンおよびその使用 |
| US11236048B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation |
| TWI685504B (zh) | 2017-06-30 | 2020-02-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 抗gitr抗體、其抗原結合片段及其醫藥用途 |
| IL319798A (en) | 2017-07-20 | 2025-05-01 | Novartis Ag | ANTI-LAG-3 Antibody Dosage Regimens and Their Uses |
| AU2018323470B2 (en) * | 2017-08-28 | 2025-04-24 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
| FI3694529T3 (fi) | 2017-10-13 | 2024-09-17 | Harpoon Therapeutics Inc | Trispesifiset proteiinit ja niiden käyttömenetelmät |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| KR20250078626A (ko) | 2018-01-12 | 2025-06-02 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| AU2019236865A1 (en) | 2018-03-23 | 2020-10-01 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
| KR102825164B1 (ko) | 2018-03-27 | 2025-06-26 | 브리스톨-마이어스 스큅 컴퍼니 | 자외선 신호를 사용한 단백질 농도의 실시간 모니터링 |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| TWI819024B (zh) | 2018-07-09 | 2023-10-21 | 美商戊瑞治療有限公司 | 結合至ｉｌｔ４的抗體 |
| MX2021000309A (es) | 2018-07-10 | 2021-04-12 | Novartis Ag | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-dion a y su uso en el tratamiento de enfermedades dependientes del dedo de zinc 2 de la familia ikaros (ikzf2). |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3104536A1 (en) | 2018-07-11 | 2020-01-16 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| CA3108796A1 (en) * | 2018-08-08 | 2020-02-13 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer and autoimmune diseases |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| EP3880711A4 (en) | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | Agonistic tumor necrosis factor receptor superfamily polypeptides |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021011351A2 (pt) | 2018-12-21 | 2021-11-16 | Novartis Ag | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica |
| EP3898674A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| WO2020128613A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1beta binding antibodies |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| EP3930767A4 (en) | 2019-02-27 | 2023-03-22 | Angiex, Inc. | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE THEREOF |
| RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| EP3973274A1 (en) | 2019-05-23 | 2022-03-30 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| KR20220016156A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐 |
| CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2021026522A2 (en) * | 2019-08-08 | 2021-02-11 | Cedars-Sinai Medical Center | Method of generating activated t cells for cancer therapy |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| KR20220087498A (ko) | 2019-10-21 | 2022-06-24 | 노파르티스 아게 | Tim-3 억제제 및 그의 용도 |
| MX2022004766A (es) | 2019-10-21 | 2022-05-16 | Novartis Ag | Terapias combinadas con venetoclax e inhibidores de tim-3. |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| IL293834A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| KR20220128389A (ko) | 2020-01-17 | 2022-09-20 | 노파르티스 아게 | 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물 |
| JP7566923B2 (ja) | 2020-03-06 | 2024-10-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｇｉｔｒ抗体およびその使用 |
| WO2021225159A1 (ja) * | 2020-05-08 | 2021-11-11 | 国立大学法人三重大学 | Ｇｉｔｒ結合性分子 |
| EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
| KR20230027056A (ko) | 2020-06-23 | 2023-02-27 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 |
| CN111732658B (zh) * | 2020-06-28 | 2022-04-26 | 英诺湖医药(杭州)有限公司 | 一组gitr单克隆抗体及其医药用途 |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2023002326A (es) | 2020-08-31 | 2023-03-21 | Bristol Myers Squibb Co | Firma de localizacion celular e inmunoterapia. |
| EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| JP2023544410A (ja) | 2020-10-05 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | タンパク質を濃縮するための方法 |
| WO2022076840A1 (en) * | 2020-10-08 | 2022-04-14 | The Brigham And Women's Hospital, Inc. | Kidney targeted delivery of drugs |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| DK4267105T3 (da) | 2020-12-28 | 2025-05-19 | Bristol Myers Squibb Co | Antistofsammensætninger og fremgangsmåder til anvendelse deraf |
| WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| AU2022209701A1 (en) | 2021-01-21 | 2023-08-31 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| TW202246334A (zh) | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN117813327A (zh) * | 2021-05-10 | 2024-04-02 | 美帝马布生物公司 | 抗gitr抗体及其用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| KR20240156411A (ko) | 2022-03-09 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치료 단백질의 일시적 발현 |
| AU2023235594A1 (en) | 2022-03-15 | 2024-09-12 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
| CR20240379A (es) | 2022-03-15 | 2024-12-11 | Compugen Ltd | Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia combinada en el tratamiento del cáncer |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| CA3258064A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE |
| JP7790683B2 (ja) | 2022-09-15 | 2025-12-23 | エルジー エナジー ソリューション リミテッド | バッテリー管理システム、バッテリーパック、電気車両及びバッテリー充電時間の予測方法 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024097328A1 (en) * | 2022-11-03 | 2024-05-10 | Incyte Corporation | Combination therapies comprising an anti-gitr antibody for treating cancers |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN117777306B (zh) * | 2023-07-04 | 2024-08-20 | 深圳豪石生物科技有限公司 | 一种靶向cldn18.2的增强型嵌合抗原受体及其用途 |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| CN117777307B (zh) * | 2023-09-26 | 2024-08-20 | 深圳豪石生物科技有限公司 | 一种cldn18.2特异性嵌合t细胞受体、嵌合t细胞受体免疫细胞及其应用 |
| US20250179203A1 (en) * | 2023-12-01 | 2025-06-05 | The General Hospital Corporation | Antibodies with fc modifications and methods of using the same |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (239)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP1026240A3 (en) | 1988-09-02 | 2004-04-07 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ES2338321T3 (es) | 1992-08-21 | 2010-05-06 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
| IL113617A (en) | 1994-05-06 | 2007-09-20 | Florence Faure | Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| DK0843557T3 (da) | 1995-07-21 | 2003-03-10 | Inst Nat Sante Rech Med | Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein |
| US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
| US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
| WO1998014179A1 (en) | 1996-10-01 | 1998-04-09 | Cima Labs Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| JP5220248B2 (ja) | 1997-08-29 | 2013-06-26 | アンチジェニックス・インコーポレイテッド | アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物 |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| DE69839179T2 (de) | 1997-10-28 | 2009-02-19 | Bando Chemical Industries, Ltd., Kobe | Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| AU2591599A (en) | 1998-02-09 | 1999-08-23 | Genentech Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US7049302B1 (en) | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| SI1141028T1 (sl) | 1998-12-23 | 2010-05-31 | Pfizer | Človeška monoklonska protitelesa proti CTLA |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| JP4093757B2 (ja) | 1999-08-24 | 2008-06-04 | メダレックス， インコーポレイテッド | ヒトｃｔｌａ−４抗体およびその使用 |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2431600C (en) | 2000-12-12 | 2012-04-17 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| WO2003006058A1 (en) | 2001-07-12 | 2003-01-23 | Wyeth | Cd25+ differential markers and uses thereof |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| US7470428B2 (en) | 2002-01-30 | 2008-12-30 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| DE60317677T2 (de) | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
| EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| PL1897548T5 (pl) | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| CA2525717A1 (en) | 2003-05-23 | 2004-12-09 | Wyeth | Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| AU2004274430A1 (en) | 2003-09-12 | 2005-03-31 | Antigenics, Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
| ES2357430T3 (es) | 2003-10-24 | 2011-04-26 | Immunaid Pty Ltd | Método de terapia. |
| CA2560742A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
| DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| ES2432091T5 (es) * | 2005-03-25 | 2022-03-18 | Gitr Inc | Moléculas de unión GITR y usos de las mismas |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US20110305713A1 (en) | 2005-10-21 | 2011-12-15 | Medical College Of Georgia Research Institute, Inc | Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells |
| AR056142A1 (es) | 2005-10-21 | 2007-09-19 | Amgen Inc | Metodos para generar el anticuerpo igg monovalente |
| US20070243184A1 (en) | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| WO2007060918A1 (ja) | 2005-11-24 | 2007-05-31 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なメモリーｃｔｌ誘導増強剤 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP1981534A4 (en) | 2006-01-07 | 2012-04-04 | Med College Georgia Res Inst | INDOLAMINE-2,3-DIOXYGENASE WAYS IN GENERATING REGULATORY T CELLS |
| EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
| GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
| CA2646671A1 (en) | 2006-03-30 | 2007-11-01 | University Of California | Methods and compositions for localized secretion of anti-ctla-4 antibodies |
| AU2007257692B2 (en) | 2006-06-12 | 2013-11-14 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| EP1894941A1 (en) | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
| AU2007319806A1 (en) | 2006-11-15 | 2008-05-22 | The Brigham And Women's Hospital, Inc. | Therapeutic uses of TIM-3 modulators |
| KR20100014588A (ko) | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| JP2008278814A (ja) * | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| EP2188630A4 (en) | 2007-10-02 | 2010-11-03 | Univ Rochester | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| DK2315756T5 (en) | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
| US7993640B2 (en) | 2008-08-06 | 2011-08-09 | Light Sciences Oncology, Inc. | Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| US9301785B2 (en) | 2008-10-21 | 2016-04-05 | K2M, Inc. | Spinal buttress plate |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| US8614295B2 (en) | 2009-02-17 | 2013-12-24 | Ucb Pharma S.A. | Antibody molecules having specificity for human OX40 |
| PT2426148E (pt) | 2009-04-27 | 2015-10-26 | Kyowa Hakko Kirin Co Ltd | Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue |
| US20120141501A1 (en) | 2009-05-29 | 2012-06-07 | Forerunner Pharma Research Co. Ltd | Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2769822C (en) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methods of modulating immune function |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| AU2010328347B2 (en) | 2009-12-07 | 2015-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing anti-tumor antibody therapy |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| CA2791383C (en) | 2010-03-05 | 2022-09-20 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20120014947A1 (en) | 2010-07-16 | 2012-01-19 | The University Of Chicago | Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system |
| EP2637691A4 (en) | 2010-11-08 | 2015-09-02 | Biovest Int Inc | MATERIALS AND METHOD FOR CONTROLLING AN IMMUNE RESPONSE TO AN EPITOP |
| WO2012075291A1 (en) | 2010-12-01 | 2012-06-07 | The Children's Hospital Of Philadelphia | Compositions and methods for treating foxp3+ treg related diseases |
| US8846042B2 (en) | 2011-05-16 | 2014-09-30 | Fabion Pharmaceuticals, Inc. | Multi-specific FAB fusion proteins and methods of use |
| CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| PH12014500089A1 (en) | 2011-07-11 | 2014-02-17 | Ichnos Sciences SA | Antibodies that bind to ox40 and their uses |
| US8920075B2 (en) | 2011-09-01 | 2014-12-30 | Halo Maritime Defense Systems, Inc. | Marine barrier and gate |
| WO2013039954A1 (en) * | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9382319B2 (en) | 2011-09-26 | 2016-07-05 | Jn Biosciences Llc | Hybrid constant regions |
| WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
| TW201333040A (zh) | 2012-01-06 | 2013-08-16 | Bioalliance Cv | 抗－輸鐵蛋白受器之抗體及其使用方法 |
| EP2817619B1 (en) | 2012-02-23 | 2018-07-25 | Sloan Kettering Institute For Cancer Research | Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment |
| WO2013142255A2 (en) | 2012-03-22 | 2013-09-26 | University Of Miami | Multi-specific binding agents |
| KR101549637B1 (ko) | 2012-06-08 | 2015-09-03 | 국립암센터 | 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도 |
| CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9540442B2 (en) | 2012-08-02 | 2017-01-10 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| DK2925350T3 (da) | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| DK2970486T3 (en) | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| AU2014233528B2 (en) | 2013-03-15 | 2019-02-28 | Abbvie Biotherapeutics Inc. | Fc variants |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| WO2015009856A2 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
| JP6449338B2 (ja) | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| WO2016028656A1 (en) | 2014-08-19 | 2016-02-25 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| MX386942B (es) | 2014-11-21 | 2025-03-19 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN108064252A (zh) | 2014-12-19 | 2018-05-22 | 达纳－法伯癌症研究所公司 | 嵌合抗原受体及其使用方法 |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| JP2018516847A (ja) | 2015-03-25 | 2018-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 生体高分子薬を送達するための組成物及び方法 |
| KR102740444B1 (ko) | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| EP3383431A4 (en) | 2015-12-02 | 2019-08-28 | Agenus Inc. | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF |
| WO2017096276A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
-
2015
- 2015-05-28 IL IL293212A patent/IL293212B2/en unknown
- 2015-05-28 SG SG11201609721WA patent/SG11201609721WA/en unknown
- 2015-05-28 WO PCT/US2015/032895 patent/WO2015184099A1/en not_active Ceased
- 2015-05-28 SI SI201531531T patent/SI3148579T1/sl unknown
- 2015-05-28 EP EP18204948.6A patent/EP3498295A1/en active Pending
- 2015-05-28 NZ NZ764826A patent/NZ764826A/en unknown
- 2015-05-28 MA MA40041A patent/MA40041B1/fr unknown
- 2015-05-28 LT LTEP15729987.6T patent/LT3148579T/lt unknown
- 2015-05-28 NZ NZ726513A patent/NZ726513A/en unknown
- 2015-05-28 DK DK15729987.6T patent/DK3148579T3/da active
- 2015-05-28 RS RS20210303A patent/RS61678B1/sr unknown
- 2015-05-28 HR HRP20210364TT patent/HRP20210364T1/hr unknown
- 2015-05-28 CN CN201580041149.7A patent/CN108064242B/zh active Active
- 2015-05-28 US US14/724,452 patent/US10155818B2/en active Active
- 2015-05-28 AU AU2015266958A patent/AU2015266958A1/en not_active Abandoned
- 2015-05-28 CA CA2949998A patent/CA2949998A1/en active Pending
- 2015-05-28 PH PH1/2016/502345A patent/PH12016502345B1/en unknown
- 2015-05-28 SM SM20210116T patent/SMT202100116T1/it unknown
- 2015-05-28 HU HUE15729987A patent/HUE053857T2/hu unknown
- 2015-05-28 MX MX2016015614A patent/MX377844B/es unknown
- 2015-05-28 JP JP2016569715A patent/JP6847666B2/ja active Active
- 2015-05-28 EP EP15729987.6A patent/EP3148579B1/en active Active
- 2015-05-28 EA EA201692458A patent/EA201692458A1/ru unknown
- 2015-05-28 CN CN202211180038.2A patent/CN115925946A/zh active Pending
- 2015-05-28 PT PT157299876T patent/PT3148579T/pt unknown
- 2015-05-28 PL PL15729987T patent/PL3148579T3/pl unknown
- 2015-05-28 SG SG10201912986PA patent/SG10201912986PA/en unknown
- 2015-05-28 KR KR1020167036746A patent/KR102433464B1/ko active Active
- 2015-05-28 TW TW109136463A patent/TW202132337A/zh unknown
- 2015-05-28 IL IL249092A patent/IL249092B/en unknown
- 2015-05-28 KR KR1020227027870A patent/KR20220116578A/ko active Pending
- 2015-05-28 PH PH1/2022/550194A patent/PH12022550194A1/en unknown
- 2015-05-28 ES ES15729987T patent/ES2860751T3/es active Active
- 2015-05-28 MA MA047849A patent/MA47849A/fr unknown
- 2015-05-28 TW TW104117180A patent/TWI709573B/zh not_active IP Right Cessation
-
2016
- 2016-11-28 MX MX2020013062A patent/MX2020013062A/es unknown
-
2018
- 2018-04-25 US US15/962,667 patent/US20180244793A1/en not_active Abandoned
- 2018-04-25 US US15/962,673 patent/US10577426B2/en active Active
- 2018-04-25 US US15/962,752 patent/US10800849B2/en active Active
- 2018-10-30 US US16/175,453 patent/US10280226B2/en active Active
-
2019
- 2019-03-15 US US16/355,268 patent/US10829559B2/en active Active
- 2019-12-27 JP JP2019238784A patent/JP2020048584A/ja active Pending
-
2020
- 2020-01-15 US US16/744,163 patent/US11401335B2/en active Active
- 2020-08-21 US US16/999,374 patent/US11897962B2/en active Active
-
2021
- 2021-01-29 AU AU2021200582A patent/AU2021200582B2/en active Active
- 2021-03-12 CY CY20211100215T patent/CY1124787T1/el unknown
-
2022
- 2022-06-22 US US17/808,248 patent/US20230039577A1/en not_active Abandoned
- 2022-08-12 AU AU2022215304A patent/AU2022215304A1/en not_active Abandoned
- 2022-12-19 JP JP2022202168A patent/JP2023021446A/ja active Pending
-
2023
- 2023-07-02 IL IL304178A patent/IL304178A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526615A5 (enExample) | ||
| US20220306744A1 (en) | Single Domain Antibodies to Programmed Cell Death (PD-1) | |
| JP6831426B2 (ja) | 腫瘍治療のための抗体組成物 | |
| JP7659501B2 (ja) | ＥＧＦＲｘＣＤ２８多特異性抗体 | |
| CN110294807B (zh) | 抗tim-3抗体 | |
| US20250361312A1 (en) | Fc binding fragments comprising an ox40 antigen-binding site | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| CN113980132B (zh) | 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途 | |
| CN107428832B (zh) | 抗pd-l1抗体 | |
| KR20190015715A (ko) | 항-ctla-4 항체 | |
| TW201233796A (en) | Human antibodies to human TNF-like ligand 1A (TL1A) | |
| TW201343675A (zh) | 抗－ｈｌａ－ｂ＊２７抗體及其用途 | |
| CN111393529B (zh) | 与ox40l非竞争结合的抗ox40抗体 | |
| US20240327544A1 (en) | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer | |
| CN113382752A (zh) | Cd137激动剂抗体及其用途 | |
| CN111971303A (zh) | 抗cd27抗体及其用途 | |
| WO2018119288A1 (en) | Anti-human cxcr3 antibodies for treatment of vitiligo | |
| KR20230006477A (ko) | Hsp70을 표적화하는 모노클로날 항체 및 이의 치료학적 용도 | |
| US20250368738A1 (en) | Anti-cd28 antibodies | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers | |
| HK40110611A (zh) | 癌症的组合治疗中针对cd40和cd137的多特异性结合剂 | |
| HK40060278A (en) | Cd137 agonist antibodies and uses thereof | |
| EP3559036A1 (en) | Anti-human cxcr3 antibodies for treatment of vitiligo |